Patents by Inventor Javier García Fernandez

Javier García Fernandez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS
    Publication number: 20230391794
    Abstract: The present subject matter provides for albumin-binding prodrugs, maytansinoid-based compounds, and uses thereof.
    Type: Application
    Filed: December 21, 2022
    Publication date: December 7, 2023
    Inventors: Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen Josef Daum
  • Maytansinoid-based drug delivery systems
    Patent number: 11572373
    Abstract: The present subject matter provides for albumin-binding prodrugs, maytansinoid-based compounds, and uses thereof.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: February 7, 2023
    Assignee: LADRX CORPORATION
    Inventors: Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen Josef Daum
  • DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE
    Publication number: 20230023537
    Abstract: The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.
    Type: Application
    Filed: June 3, 2022
    Publication date: January 26, 2023
    Inventors: Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
  • HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE
    Publication number: 20220267283
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: April 26, 2022
    Publication date: August 25, 2022
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Kunzhong Jian, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • Delivery systems for controlled drug release
    Patent number: 11384104
    Abstract: The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: July 12, 2022
    Assignee: CENTURION BIOPHARMA CORPORATION
    Inventors: Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
  • Albumin-binding prodrugs of auristatin E derivatives
    Patent number: 11377473
    Abstract: The present disclosure provides for albumin-binding prodrugs of auristatin E derivatives and uses thereof.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: July 5, 2022
    Assignee: CENTURION BIOPHARMA CORPORATION
    Inventors: Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen Josef Daum
  • Heterocyclic compounds for cancer imaging and treatment and methods for their use
    Patent number: 11345670
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: May 31, 2022
    Assignees: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Kunzhong Jian, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • IMAGING AGENTS FOR RADIOLABELING EXOGENOUS AND ENDOGENOUS ALBUMIN
    Publication number: 20210353783
    Abstract: The present disclosure provides albumin-binding radioactive metal complexes and uses thereof, including diagnosing and treating disease.
    Type: Application
    Filed: July 16, 2019
    Publication date: November 18, 2021
    Inventors: Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Steffen Daum, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda
  • ALBUMIN-BINDING PRODRUGS OF AURISTATIN E DERIVATIVES
    Publication number: 20200385421
    Abstract: The present disclosure provides for albumin-binding prodrugs of auristatin E derivatives and uses thereof.
    Type: Application
    Filed: November 30, 2018
    Publication date: December 10, 2020
    Inventors: Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen Josef Daum
  • MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS
    Publication number: 20200385403
    Abstract: The present subject matter provides for albumin-binding prodrugs, maytansinoid-based compounds, and uses thereof.
    Type: Application
    Filed: November 30, 2018
    Publication date: December 10, 2020
    Inventors: Felix Kratz, Khalid Abu Ajaj, Anna Warnecke, Friederike I. Nollmann, Stephan David Koester, Javier Garcia Fernandez, Lara Pes, Heidi-Kristin Walter, Johannes Pall Magnusson, Serghei Chercheja, Patricia Perez Galan, Federico Medda, Steffen Josef Daum
  • HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE
    Publication number: 20200325106
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: May 1, 2020
    Publication date: October 15, 2020
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Kunzhong Jian, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • Heterocyclic compounds for cancer imaging and treatment and methods for their use
    Patent number: 10654811
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: May 19, 2020
    Assignees: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Kunzhong Jian, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE
    Publication number: 20190002484
    Abstract: The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.
    Type: Application
    Filed: June 17, 2016
    Publication date: January 3, 2019
    Inventors: Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
  • HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE
    Publication number: 20180327368
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: January 13, 2016
    Publication date: November 15, 2018
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA UNIVERSITY-INDUSTRY LIAISON OFFICE, BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: Raymond John ANDERSEN, Javier Garcia FERNANDEZ, Kunzhong JIAN, Marianne Dorothy SADAR, Nasrin R. MAWJI, Carmen Adriana BANUELOS
  • BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE
    Publication number: 20180235925
    Abstract: Compounds having a structure of Formula I: wherein G, a, Q, L2, R1, R2, R3, R4, R5 and R6 are as defined herein are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: November 22, 2017
    Publication date: August 23, 2018
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Marianne Dorothy Sadar, Nasrin Mawji, Carmen Adriana Banuelos, Jun Wang
  • HALOGENATED COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE
    Publication number: 20160367707
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.
    Type: Application
    Filed: May 17, 2016
    Publication date: December 22, 2016
    Inventors: Raymond John Andersen, Carmen Adriana Banuelos, Javier GARCIA FERNANDEZ, Yusuke IMAMURA, Jian KUNZHONG, Nasrin R. MAWJI, Marianne Dorothy SADAR, Jun WANG, Amy (Hsing Chen) Tien
  • Bisphenol derivatives and their use as androgen receptor activity modulators
    Patent number: 9388112
    Abstract: This invention provides bisphenol derivatives having a structure of formula 1. Said compounds are modulators of the androgen receptor activity and are useful in the treatment of various diseases, including prostate cancer, breast cancer, ovarian cancer, endometrial cancer, acne, ovarian cysts, polycystic ovarian disease, age-related macular degeneration, precocious puberty, hirsutism and hair loss.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: July 12, 2016
    Assignees: The University of British Columbia, Brittish Columbia Cancer Agency Branch
    Inventors: Marianne D. Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos, Raymond J. Andersen, Javier Garcia Fernandez
  • Halogenated compounds for cancer imaging and treatment and methods for their use
    Patent number: 9375496
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: June 28, 2016
    Assignees: British Columbia Cancer Agency Branch, The University of British Columbia
    Inventors: Raymond John Andersen, Carmen Adriana Banuelos, Javier Garcia Fernandez, Yusuke Imamura, Jian Kunzhong, Nasrin R. Mawji, Marianne Dorothy Sadar, Jun Wang, Amy (Hsing Chen) Tien
  • ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20160068466
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein, and wherein at least one of R1, R2 or R3 is an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: September 3, 2015
    Publication date: March 10, 2016
    Applicants: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Raymond J. Andersen, Marianne D. Sadar, Javier Garcia Fernandez, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos
  • Ester derivatives of androgen receptor modulators and methods for their use
    Patent number: 9173939
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein, and wherein at least one of R1, R2 or R3 is an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: November 3, 2015
    Assignees: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Raymond J. Andersen, Marianne D. Sadar, Javier Garcia Fernandez, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos